Credit: ESO/WFI (Optical); MPIfR/ESO/APEX/A.Weiss et al. (Submillimetre); NASA/CXC/CfA/R.Kraft et al. (X-ray)

Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath


Purpose: To compare PREDICT and CancerMath, two widely used prognostic models for invasive breast cancer, taking into account their clinical utility. Furthermore, it is unclear whether these models could be improved. Experimental Design: A dataset of 5729 women was used for model development. A Bayesian variable selection algorithm was implemented to stochastically search for important interaction terms among the predictors. The derived models were then compared in three independent datasets (n = 5534). We examined calibration, discrimination and performed decision curve analysis. Results: CancerMath demonstrated worse calibration performance compared to PREDICT in oestrogen receptor (ER)-positive and ER-negative tumours. The decline in discrimination performance was -4.27% (-6.39 - -2.03) and -3.21% (-5.9 - -0.48) for ER-positive and ER-negative tumours, respectively. Our new models matched the performance of PREDICT in terms of calibration and discrimination, but offered no improvement. Decision curve analysis showed predictions for all models were clinically useful for treatment decisions made at risk thresholds between 5% and 55% for ER-positive tumours and at thresholds of 15% to 60% for ER-negative tumours. Within these threshold ranges, CancerMath provided the lowest clinical utility amongst all the models. Conclusions: Survival probabilities from PREDICT offer both improved accuracy and discrimination over CancerMath. Using PREDICT to make treatment decisions offers greater clinical utility than CancerMath over a range of risk thresholds. Our new models performed as well as PREDICT, but no better, suggesting that, in this setting, including further interaction terms offers no predictive benefit.

In Clinical Cancer Research